IL115811A0 - Method for treating anxiety - Google Patents
Method for treating anxietyInfo
- Publication number
- IL115811A0 IL115811A0 IL11581195A IL11581195A IL115811A0 IL 115811 A0 IL115811 A0 IL 115811A0 IL 11581195 A IL11581195 A IL 11581195A IL 11581195 A IL11581195 A IL 11581195A IL 115811 A0 IL115811 A0 IL 115811A0
- Authority
- IL
- Israel
- Prior art keywords
- branched
- straight
- alkyl
- halogen
- phenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/332,186 US5488056A (en) | 1994-10-31 | 1994-10-31 | Method for treating anxiety |
US08/336,454 US5708014A (en) | 1994-10-31 | 1994-11-09 | Method for treating anxiety |
Publications (1)
Publication Number | Publication Date |
---|---|
IL115811A0 true IL115811A0 (en) | 1996-01-19 |
Family
ID=26988104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL11581195A IL115811A0 (en) | 1994-10-31 | 1995-10-30 | Method for treating anxiety |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0709094B1 (de) |
JP (1) | JPH10508028A (de) |
AT (1) | ATE191344T1 (de) |
AU (1) | AU4139096A (de) |
CA (1) | CA2202776A1 (de) |
DE (1) | DE69516076T2 (de) |
DK (1) | DK0709094T3 (de) |
ES (1) | ES2144581T3 (de) |
GR (1) | GR3033839T3 (de) |
IL (1) | IL115811A0 (de) |
PT (1) | PT709094E (de) |
WO (1) | WO1996013167A1 (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5852037A (en) * | 1995-11-13 | 1998-12-22 | Eli Lilly And Company | Method for treating anxiety |
US5763457A (en) * | 1995-11-13 | 1998-06-09 | Eli Lilly And Company | Method for treating anxiety |
EP0821956A1 (de) * | 1996-08-01 | 1998-02-04 | Eli Lilly And Company | Verfahren zur Behandlung disruptiver Verhaltensstörungen |
EP0821957A3 (de) * | 1996-08-01 | 1998-04-22 | Eli Lilly And Company | Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von Drogenmissbrauch |
EP0821958A3 (de) * | 1996-08-01 | 1998-07-08 | Eli Lilly And Company | Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von übermässiger Streitsucht |
US6090829A (en) * | 1996-08-01 | 2000-07-18 | Eli Lilly And Company | Method for treating excessive aggression |
US6043258A (en) * | 1996-08-01 | 2000-03-28 | Eli Lilly And Company | Method for treating disruptive behavior disorders with xanomeline |
EP0821959A3 (de) * | 1996-08-01 | 1998-09-16 | Eli Lilly And Company | Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin zur Behandlung von Nikotin-Entzug |
US6117890A (en) * | 1996-08-01 | 2000-09-12 | Eli Lilly And Company | Method for treating bipolar disorder |
EP0821954A1 (de) * | 1996-08-01 | 1998-02-04 | Eli Lilly And Company | Verfahren zur Behandlung von geistiger Zurückgebliebenheit |
DE69710526T2 (de) * | 1996-08-01 | 2002-10-02 | Eli Lilly And Co., Indianapolis | Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von bipolaren Störungen |
US6034108A (en) * | 1997-07-28 | 2000-03-07 | Eli Lilly And Company | Method for treating mental retardation |
DE102004046799B4 (de) * | 2004-09-27 | 2007-02-15 | Volker Endres | Vorrichtung zum Stoppen einer schwenkbaren Einrichtung |
WO2007075297A2 (en) * | 2005-12-27 | 2007-07-05 | University Of Toledo | Muscarinic agonists and methods of use thereof |
WO2009128057A2 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
WO2009140483A1 (en) | 2008-05-15 | 2009-11-19 | University Of Toledo | Muscarinic agonists as cognitive enhancers |
WO2012149524A1 (en) | 2011-04-29 | 2012-11-01 | The University Of Toledo | Muscarinic agonists as enhancers of working memory and cognitive flexibility |
WO2021097427A1 (en) | 2019-11-15 | 2021-05-20 | Karuna Therapeutics, Inc. | Xanomeline derivatives and methods for treating neurological disorders |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5043345A (en) * | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
US5824004A (en) * | 1990-06-18 | 1998-10-20 | The Procter & Gamble Company | Stretchable absorbent articles |
US5376668A (en) * | 1990-08-21 | 1994-12-27 | Novo Nordisk A/S | Heterocyclic compounds |
DE69430816T2 (de) * | 1993-08-19 | 2002-12-19 | Novo Nordisk A/S, Bagsvaerd | Verwendung von Piperidin-Derivaten in der Behandlung von Schizophrenie |
-
1995
- 1995-10-30 DK DK95307739T patent/DK0709094T3/da active
- 1995-10-30 AT AT95307739T patent/ATE191344T1/de not_active IP Right Cessation
- 1995-10-30 WO PCT/US1995/014053 patent/WO1996013167A1/en active Search and Examination
- 1995-10-30 PT PT95307739T patent/PT709094E/pt unknown
- 1995-10-30 AU AU41390/96A patent/AU4139096A/en not_active Abandoned
- 1995-10-30 JP JP8514811A patent/JPH10508028A/ja active Pending
- 1995-10-30 ES ES95307739T patent/ES2144581T3/es not_active Expired - Lifetime
- 1995-10-30 IL IL11581195A patent/IL115811A0/xx unknown
- 1995-10-30 DE DE69516076T patent/DE69516076T2/de not_active Expired - Fee Related
- 1995-10-30 EP EP95307739A patent/EP0709094B1/de not_active Expired - Lifetime
- 1995-10-30 CA CA002202776A patent/CA2202776A1/en not_active Abandoned
-
2000
- 2000-06-30 GR GR20000401540T patent/GR3033839T3/el not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0709094A3 (de) | 1996-05-08 |
ES2144581T3 (es) | 2000-06-16 |
DE69516076D1 (de) | 2000-05-11 |
EP0709094B1 (de) | 2000-04-05 |
WO1996013167A1 (en) | 1996-05-09 |
GR3033839T3 (en) | 2000-10-31 |
DE69516076T2 (de) | 2000-09-14 |
EP0709094A2 (de) | 1996-05-01 |
JPH10508028A (ja) | 1998-08-04 |
PT709094E (pt) | 2000-08-31 |
DK0709094T3 (da) | 2000-07-10 |
CA2202776A1 (en) | 1996-05-09 |
ATE191344T1 (de) | 2000-04-15 |
AU4139096A (en) | 1996-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL115811A0 (en) | Method for treating anxiety | |
DE69409913D1 (de) | Methode zur Hemmung der Proliferation weiche Muskelzellen und der Restenose | |
ES8503351A1 (es) | Un procedimiento para preparar nuevos derivados de imidazo (4,5-c) piridina (como divisional de la solicitud de patente de invencion num. 517.193, presentada el 8 de noviembre de 1982) | |
CA2136553A1 (en) | 7-(2-aminoethyl)-Benzothiazolones | |
PL289935A1 (en) | Method of obtaining novel derivatives of 4h-pyrido-(1,2-a) pyrimidone-4 | |
ES2160649T3 (es) | Nuevos compuestos lactamicos y procedimientos para su preparacion. | |
HK1006284A1 (en) | Thiazolidine derivatives having anti-hypertensive activity and their therapeutic use | |
MY132085A (en) | Methods for inhibiting bone prosthesis degeneration | |
FR2610934B1 (fr) | Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
NZ219012A (en) | Glu-asp-ala tripeptide derivatives and pharmaceutical compositions | |
GR3033783T3 (en) | Method for treating anxiety using an azabicyclic oxadiazole or thiadiazole compound | |
PT82550A (en) | 1,3 oxathiane derivatives | |
PL300276A1 (en) | Novel derivatives of 3-oxadiazolyl-5,6,7,8-tetrahydro-1,6-naphtyridine, novel derivatives of 5,6,7,8-tetrahydro-1,6-naphtyridine and method of obtaining 1,6-naphtyridine derivatives | |
NZ235130A (en) | Cephalosporin derivatives; oxygen and carbon analogues thereof; pharmaceutical compositions; methods of preparation and treatment | |
DE3851449D1 (de) | Cephalosporinderivate, Verfahren zu ihrer Herstellung und antibakterielle Mittel. | |
HUP0002054A2 (hu) | N-4-(nitro-metil-szulfonil)-fenil-alkánamid és -benzolszulfonamid-származékok, alkalmazásuk, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények | |
DE69822234D1 (de) | Verwendung von Olanzapin zur Herstellung eines Arzneimittels zur Neuroprotektion |